ReviewGene therapy2007
Plasmid-based gene therapy of diabetes mellitus.
Review in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 68 citations in OpenAlex.
- The Role of Gene Therapy and RNA-Based Therapeutic Strategies in Diabetes.International journal of molecular sciences · 2025Review
- Therapeutic Interventions for Diabetes Mellitus-associated Complications.Current diabetes reviews · 2025Review
- DNA Vaccines in Pigs: From Immunization to Antigen Identification.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Gold nanoparticle coatings as efficient adenovirus carriers to non-infectable stem cells.RSC advances · 2019Article
- Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome.PloS one · 2018Article
- Engineered Epidermal Progenitor Cells Can Correct Diet-Induced Obesity and Diabetes.Cell stem cell · 2017Article
- Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.Human gene therapy methods · 2015Article
- A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.Human vaccines & immunotherapeutics · 2015Article
- A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.Human vaccines & immunotherapeutics · 2014Article
- Article
- Contactless magneto-permeabilization for intracellular plasmid DNA delivery in-vivo.Human vaccines & immunotherapeutics · 2012Article
- Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2012Article
- Antigen-specific therapeutic approaches in Type 1 diabetes.Cold Spring Harbor perspectives in medicine · 2012Review
- Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.Gene therapy · 2011Article
- Encapsulation of plasmid DNA in calcium phosphate nanoparticles: stem cell uptake and gene transfer efficiency.International journal of nanomedicine · 2011Article
- Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1.The journal of gene medicine · 2010Article
- Efficient gene delivery and silencing of mouse and human pancreatic islets.BMC biotechnology · 2010Article
- Diabetes mellitus: new challenges and innovative therapies.The EPMA journal · 2010Article
- Article
- Electroporation advances in large animals.Current gene therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type I diabetes mellitus (T1D) is due to a loss of immune tolerance to islet antigen and thus, there is intense interest in developing therapies that can re-establish it. Tolerance is maintained by complex mechanisms that include inhibitory molecules and several types of regulatory T cells (Tr). A major historical question is whether gene therapy can be employed to generate Tr cells. This review shows that gene transfer of immunoregulatory molecules can prevent T1D and other autoimmune diseases. In our studies, non-viral gene transfer is enhanced by in vivo electroporation (EP). This technique can be used to perform DNA vaccination against islet cell antigens and when combined with appropriate immune ligands results in the generation of Tr cells and protection against T1D. In vivo EP can also be applied for non-immune therapy of diabetes. It can be used to deliver protein drugs such as glucagon-like peptide 1 (GLP-1), leptin or transforming growth factor beta (TGF-beta). These act in T1D or type II diabetes (T2D) by restoring glucose homeostasis, promoting islet cell survival and growth or improving wound healing and other complications. Furthermore, we show that in large animals EP can deliver peptide hormones, such as growth hormone releasing hormone (GHRH). We conclude that the non-viral gene therapy and EP represent a safe and efficacious approach with clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.